<DOC>
	<DOCNO>NCT00099619</DOCNO>
	<brief_summary>This study two treatment sequence two treatment period assess safety efficacy exenatide treatment patient type 2 diabetes inadequate glycemic control use metformin sulfonylurea insulin next appropriate step diabetes treatment .</brief_summary>
	<brief_title>Comparing Exenatide Insulin Glargine Type 2 Diabetes Patients Whom Insulin Next Appropriate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Main Treated stable dose metformin sulfonylurea least 3 month prior screen . HbA1c 7.1 % 11.0 % , inclusive . Insulin therapy next appropriate step diabetes treatment . Body Mass Index ( BMI ) &gt; 25 kg/m2 &lt; 40 kg/m2 . Main Patient previously study involve exenatide glucagonlike peptide1 analog . Treated insulin , thiazolidinediones , alphaglucosidase inhibitor , meglitinides within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>